Bioactivity profiling with parallel mass spectrometry reveals an assemblage of green tea metabolites affording protection against human huntingtin and α-synuclein toxicity

Journal of Agricultural and Food Chemistry

Volumn 55, Issue 23, 2007, Pages 9450-9456

  Williams, Russell B ^a   Gutekunst, Will R ^a   Joyner, P Matthew ^a   Duan, Wenzhen ^b   Li, Qing ^b   Ross, Christopher A ^b   Williams, Todd D ^c   Cichewicz, Robert H ^a  

^a UNIVERSITY OF OKLAHOMA   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF KANSAS   (United States)

Author keywords

synuclein; Bioassay; Catechins; Huntingtin; Huntington's disease; Mass spectrometry; Natural products; Neuroprotective, green tea; Parkinson's disease; Protection; Protein aggregation; Saccharomyces cerevisiae; Yeast

Indexed keywords

ALPHA SYNUCLEIN; CATECHIN; HD PROTEIN, HUMAN; NERVE PROTEIN; NUCLEAR PROTEIN; PLANT EXTRACT; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CHEMISTRY; DRUG ANTAGONISM; GENETICS; HUMAN; MASS SPECTROMETRY; MUTATION; SACCHAROMYCES CEREVISIAE; TEA;

ALPHA-SYNUCLEIN; CATECHIN; HUMANS; MASS SPECTROMETRY; MUTATION; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; PLANT EXTRACTS; RECOMBINANT PROTEINS; SACCHAROMYCES CEREVISIAE; TEA;

SACCHAROMYCES CEREVISIAE;

EID: 36749006111     PISSN: 00218561     EISSN: None     Source Type: Journal    
DOI: 10.1021/jf072241x     Document Type: Article

References (35)

1. Ross, C. A.; Poirier, M. A. Protein aggregation and neurodegenerative disease. Nat. Med. 2004, 10, S10-S17.
2. Uversky, V. N.; Fernandez, A.; Fink, A. L. Structural and Conformational Prerequisites for Amyloidogenesis. In Protein Misfolding, Aggregation, and Conformational Diseases. Part A: Protein Aggregation and Conformational Diseases; Uversky, V. N., Fink, A. L., Eds.; Springer: Singapore, 2006; Vol. 4, pp 1-20.
3. Ross, C. A.; Poirier, M. A. What is the role of protein aggregation in neurodegeneration? Nat. Rev. Mol. Cell Biol. 2005, 6, 891-898.
4. Rosenblatt, A.; Liang, K. Y.; Zhou, H.; Abbott, M. H.; Gourley, L. M.; Margolis, R. L.; Brandt, J.; Ross, C. A. The association of CAG repeat length with clinical progression in Huntington disease. Neurology 2006, 66, 1016-1020.
5. Forman, M. S.; Trojanowski, J. Q.; Lee, V. M. Y. Neurodegenerative diseases: A decade of discoveries paves the way for therapeutic breakthroughs. Nat. Med. 2004, 10, 1055-1063.
6. Mukaetova-Ladinska, E. B.; McKeith, I. G. Pathophysiology of synuclein aggregation in Lewy body disease. Mech. Ageing Dev. 2006, 127, 188-202.
7. Fink, A. L. The aggregation and fibrillation of α-synuclein. Acc. Chem. Res. 2006, 39, 628-634.
8. Jakobsen, L. D.; Jensen, P. H. Parkinson's Disease: α-Synuclein and Parkin in Protein Aggregation and the Reversal of Unfolded Protein Stress. In Protein Misfolding and Disease: Principles and Protocols; Bross, P., Gregersen, N., Eds.; Humana Press: Totowa, NJ, 2003; Vol. 232, pp 57-66.
9. Zarranz, J. J.; Alegre, J.; Gómez-Esteban, J. C.; Lezcano, E.; Ros, R.; Ampuero, I.; Vidal, L.; Hoenicka, J.; Rodriguez, O.; Atarés, B.; Llorens, V.; Tortosa, E. G.; Ser, T. d.; Muñoz, D. G.; Yebenes, J. G. D. The new mutation, E46K, of α-synuclein causes parkinson and Lewy body dementia. Ann. Neurol. 2004, 55, 164-173.
10. Outeiro, T. F.; Giorgini, F. Yeast as a drug discovery platform in Huntington's and Parkinson's diseases. Biotechnol. J. 2006, 1, 258-269.
11. Coughlan, C. M.; Brodsky, J. L. Use of yeast as a model system to investigate protein conformational diseases. Mol Biotechnol. 2005, 30, 171-180.
12. Zhang, X.; Smith, D. L.; Meriin, A. B.; Engemann, S.; Russel, D. E.; Roark, M.; Washington, S. L.; Maxwell, M. M.; Marsh, J. L.; Thompson, L. M.; Wanker, E. E.; Young, A. B.; Housman, D. E.; Bates, G. P.; Sherman, M. Y.; Kazantsev, A. G. A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo. Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 892-897.
13. Outeiro, T. F.; Lindquist, S. Yeast cells provide insight into α-synuclein biology and pathobiology. Science 2003, 302, 1772-1775.
14. Mandel, S. A.; Avramovich-Tirosh, Y.; Reznichenko, L.; Zheng, H.; Weinreb, O.; Amit, T.; Youdim, M. B. H. Multifunctional activities of green tea catechins in neuroprotection. Modulation of cell survival genes, iron-dependent oxidative stress and PKC signaling pathway. Neurosignals 2005, 14, 46-60.
15. Walsh, L.; Hastwell, P. W.; Keenan, P. O.; Knight, A. W.; Billinton, N.; Walmsley, R. M. Genetic modification and variations in solvent increase the sensitivity of the yeast RAD54-GFP genotoxicity assay. Mutagenesis 2005, 20, 317-327.
16. Dixon, C.; Mathias, N.; Zweig, R. M.; Davis, D. A.; Gross, D. S. α-Synuclein targets the plasma membrane via the secretory pathway and induces toxicity in yeast. Genetics 2005, 170, 47-59.
17. Inoue, H.; Nojima, H.; Okayama, H. High efficiency transformation of Escherichia coli with plasmids. Gene 1990, 96, 23-28.
18. Gietz, R. D.; Woods, R. A. Transformation of yeast by lithium acetate/single-stranded carrier DNA/polyethylene glycol method. Methods Enzymol. 2002, 350, 87-96.
19. Assay Guidance Manual, version 4.1. http://www.ncgc.nih.gov/guidance/ manual_toc.html (accessed July 17, 2007).
20. Wang, W.; Duan, W.; Igarashi, S.; Morita, H.; Nakamura, M.; Ross, C. A. Compounds blocking mutant huntingtin toxicity identified using a Huntington's disease neuronal cell model. Neurobiol. Dis. 2005, 20, 500-508.
21. 13C NMR assignments of some green tea polyphenols. Magn. Reson. Chem. 1996, 34, 887-890.
22. Abd El Mohsen, M. M.; Kuhnle, G.; Rechner, A. R.; Schroeter, H.; Rose, S.; Jenner, P.; Rice-Evans, C. A. Uptake and metabolism of epicatechin and its access to the brain after oral ingestion. Free Radical Biol. Med. 2002, 33, 1693-1702.
23. 3H]-(-)-epigallocatechin gallate, a cancer preventive tea polyphenol, in mouse tissue. Carcinogenesis 1998, 19, 1771-1776.
24. Kocisko, D. A.; Baron, G. S.; Rubenstein, R.; Chen, J.; Kuizon, S.; Caughey, B. New inhibitors of scrapie-associated prion protein formation in a library of 2,000 drugs and natural products. J. Virol. 2003, 77, 10288-10294.
25. Masuda, M.; Suzuki, N.; Taniguchi, S.; Oikawa, T.; Nonaka, T.; Iwatsubo, T.; Hisanaga, S.; Goedert, M.; Hasegawa, M. Small molecule inhibitors of α-synuclein filament assembly. Biochemistry 2006, 45, 6085-6094.
26. Ono, K.; Yamada, M. Antioxidant compounds have potent antifibrillogenic and fibril-destabilizing effects for α-synuclein fibrils invitro. J. Neurochem. 2006, 97, 105-115.
27. Caughey, B.; Lansbury, P. T. Protofibrils, pores, fibrils, and neurodegeneration: Separating the responsible protein aggregates from the innocent bystanders. Annu. Rev. Neurosci. 2003, 26, 267-298.
28. Agorogiannis, E. I.; Agorogiannis, G. I.; Papadimitriou, A.; Hadjigeorgiou, G. M. Protein misfolding in neurodegenerative diseases. Neuropathol. Appl. Neurobiol. 2004, 30, 215-224.
29. Griffioen, G.; Duhamel, H.; Van Damme, N.; Pellens, K.; Zabrocki, P.; Pannecouque, C.; van Leuven, F.; Winderickx, J.; Wera, S. A yeast-based model of α-synucleinopathy identifies compounds with therapeutic potential. Biochim. Biophys. Acta 2006, 1762, 312-318.
30. Ehrnhoefer, D. E.; Duennwald, M.; Markovic, P.; Wacker, J. L.; Engemann, S.; Roark, M.; Legleiter, J.; Marsh, J. L.; Thompson, L. M.; Lindquist, S.; Muchowski, P. J.; Wanker, E. E. Green tea (-)-epigallocatechin-gallate modulates early events in huntingtin misfolding and reduces toxicity in Huntington's disease models. Hum. Mol. Genet. 2006, 15, 2743-2751.
31. Bastianetto, S.; Yao, Z.-X.; Papadopoulos, V.; Quirion, R. Neuroprotective effects of green and black teas and their catechin gallate esters against β-amyloid-induced toxicity. Eur. J. Neurosci. 2006, 23, 55-64.
32. Reznichenko, L.; Amit, T.; Zheng, H.; Avramovich-Tirosh, Y.; Youdim, M. B. H.; Mandel, S. Reduction of iron-regulated amyloid precursor protein and β-amyloid peptide by (-)-epigallocatechin-3-gallate in cell cultures: Implications for iron chelation in Alzheimer's disease. J. Neurochem. 2006, 97, 527-536.
33. Jung, J. Y.; Han, C. R.; Jeong, Y. J.; Kim, H. J.; Lim, H. S.; Lee, K. H.; Park, H. O.; Oh, W. M.; Kim, S. H.; Kim, W. J. Epigallocatechin gallate inhibits nitric oxide-induced apoptosis in rat PC12 cells. Neurosci. Lett. 2007, 411, 222-227.
34. Maeta, K.; Nomura, W.; Takatsume, Y.; Izawa, S.; Inoue, Y. Green tea polyphenols function as prooxidants to activate oxidative-stress-responsive transcription factors in yeasts. Appl. Environ. Microbiol. 2007, 73, 572-580.
35. Ramassamy, C. Emerging role of polyphenolic compounds in the treatment of neurodegenerative diseases: A review of their intracellular targets. Eur. J. Pharmacol. 2006, 545, 51-64.